Business Countywide
May 4, 2000
San Diego
WAM! Loyalty.com, the creator and marketer of WAM! America's
Other Money, announced partnerships with ePacific.com, the
company's technology provider and developer, and "A" Plus Strategic
Alliances, which will offer additional benefits to WAM! cardholders.
According to WAM!, these partnerships will allow the company to maximize
its cardholder's buying power.
Created by the founders of A La Carte International and the
Nationwide Press Pass program, WAM! is a form of currency that is accepted
at various merchants around the United States and on the Internet.
A team led by Science Applications International Corp. has been
selected by the Army Aviation and Missile Command to provide advisory and
assistance services in support of AMCOM and program executive officers of
Air and Missile Defense, Aviation and Tactical Missiles missions. The
Omnibus 2000 contract will be a five-year, multiple-award best-value
contract with a potential value of $1.25 billion.
The procurement covered three categories of work including technical,
programmatic and logistics. Awards will be made to 12 companies in the
three categories. SAIC won one of two prime awards in the technical
full-open category, was on a winning team in the logistics category and on
two winning teams in the programmatic category.
SAIC is the nation's largest employee-owned research and engineering
company, providing information technology and systems integration products
and services to government and commercial customers.
La Jolla
La Jolla Pharmaceutical Co. announced additional positive
results from the Phase II/III clinical trial of its lupus drug candidate,
LJP 394. Previously, the company had announced encouraging results for a
group of patients with high-affinity antibodies to the drug, based on
samples available at the time.
LJP 394 is designed to arrest the production of antibodies to dsDNA in
lupus patients without suppressing the healthy functions of the immune
system. LJP 394 is an investigational drug, and safety and efficacy have
not been established at this time. However, clinical trial results to date
suggest that LJP 394 is well-tolerated.
La Jolla Pharmaceutical is focused on the research and development of
therapeutic compounds to treat antibody-mediated diseases such as lupus,
antibody-mediated thrombosis, myocardial infarction, deep-vein thrombosis,
and recurrent fetal loss and organ rejection in xenotransplantation.
Rancho Santa Fe
Rancho Santa Fe Technology Inc., a mission critical network
communication service, has completed the installation of a sophisticated
structured cabling system for the Novartis biotech facility in La
Jolla.
Rancho Santa Fe Technology was retained by DPR Construction, the
general contractor for Novartis' new West Coast facility, which houses the
Novartis Institute for Functional Genomics and the Novartis Agricultural
Discovery Institute. The fast-track project was completed in two phases by
DPR Construction with initial work completed in four months and the entire
project in 5.5 months.
Rancho Santa Fe Technology installed more than 800,000 linear feet, or
more than 151 miles of high-speed data-transmission cable to network 475
workstations on the first floor and 350 workstations on the second floor,
each with four cables per outlet -- two for data, one for voice and one
multipurpose outlet.
joe.britton@sddt.com
|
.gif)
.gif)
.gif)
.gif)